Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Price Up 6.6%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) traded up 6.6% during trading on Monday . The stock traded as high as 1.69 and last traded at 1.69. 3,724,107 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 3,849,882 shares. The stock had previously closed at 1.58.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Oppenheimer restated an “outperform” rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley lifted their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research report on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insiders Place Their Bets

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately 110,934,724.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CATX. Perkins Capital Management Inc. acquired a new stake in Perspective Therapeutics during the 3rd quarter worth about $731,000. HighTower Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth approximately $314,000. Taylor & Morgan Wealth Management LLC increased its position in shares of Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Perspective Therapeutics in the 3rd quarter valued at $42,000. Finally, ZWJ Investment Counsel Inc. purchased a new stake in Perspective Therapeutics in the 1st quarter valued at $26,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.